Skip to Content Skip to Search

Investors

Information for investors including Annual Reports, Financial Calendar, Shareholders' Information and Quarterly Trading Result.

Investing in GSK

Our business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk and improve our long-term financial performance. These priorities are: grow a balanced global business, deliver more products of value, and simplify the operating model. Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

Grow a balanced business

We have been creating a more balanced business and product portfolio, capable of delivering sustainable sales and earnings growth and improved returns to shareholders.

This is centred on our three business areas of Pharmaceuticals, Vaccines and Consumer Healthcare.

Deliver more products of value

We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers. This is underpinned by a focus on improving productivity and rates of return in R&D.

Simplify the operating model

As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient. This frees up resources to reinvest elsewhere in the business, or return to shareholders wherever we see the most attractive returns.

Responsible business

Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

General Meetings & Annual Reports

Information for shareholders including Notices, Annual Reports and Quarterly Trading Result

Financial Calendar

Scheduled timeline for the release of Financial Results

Event Date
Audited Financial Statement March
Quarter 1 Un-audited Results April
Quarter 2 Un-audited Results July
Quarter 3 Un-audited Results October

Contact details

Investors and Analysts

Investors and Analysts should contact :

Corporate Communications
GlaxoSmithKline Consumer Nigeria PLC
1, Industrial Avenue, Ilupeju, Lagos
Tel: +234-1-2711000, +234-1-3249000
E-mail: ng.investors@gsk.com
Website: www.ng.gsk.com

Individual Shareholders should contact:

The Company Secretary
GlaxoSmithKline Consumer Nigeria PLC
1, Industrial Avenue, Ilupeju, Lagos
Tel: +234-1-2711000, +234-1-3249000
E-mail: ng.investors@gsk.com
Website: www.ng.gsk.com

Registrars and Transfer Office

Greenwich Registrars & Data Solutions Limited (formerly GTL Registrars)
No. 274, Muritala Muhammed Way,
Yaba, Lagos State.
Tel: +234-1-2917747, +234-1-2917745, +234-1-2917714

External Auditors

Akintola Williams Deloitte
Civic Towers Ozumba Mbadiwe Road
Victoria Island
Lagos State
Tel: +234 -1-2717800